{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-062807","form_type":"8-K","ticker":"ADTX","cik":"0001726711","company_name":"Aditxt, Inc.","filed_at":"2025-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.813827+00:00","generated_at":"2026-05-18T08:46:50.422182+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aditxt CEO presents at investor event; updates on Evofem close, Pearsanta commercialization, crypto strategy","bullets":["CEO Amro Albanna presented at Wall Street Reporter's Next Super Stock livestream on July 8, 2025, discussing business model as 'publicly owned innovation accelerator'.","Pearsanta validation ongoing; expects to commercialize prostate cancer and endometriosis tests by Q1 2026.","Evofem acquisition (women's health) expected to close by end of September 2025, subject to financing, as anchor for Adifem.","Announced Bitcoin/crypto treasury strategy to broaden shareholder base; market cap ~$5M.","Adimune plans to file for human trials Q4 2025/Q1 2026 for stiff person syndrome, type 1 diabetes, psoriasis."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-062807","json":"https://secwatch.observer/filing/0001213900-25-062807.json","markdown":"https://secwatch.observer/filing/0001213900-25-062807.md","text":"https://secwatch.observer/filing/0001213900-25-062807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025062807/0001213900-25-062807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025062807/ea0248501-8k_aditxt.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:46:50.422182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}